Bioasis Technologies (BIOAF) 0.9496 $BIOAF
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Pipeline Review, H2 2015 - 10 Companies & 13 Drug Profiles
M2 - Mon Oct 05, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2932sl/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - ArmaGen Technologies, Inc. - Athersys, Inc. - biOasis Technologies Inc. - Fate Therapeutics, Inc. - OPKO Health, Inc. - PTC Therapeutics, Inc. - RegenxBio Inc. - Sangamo BioSciences, Inc. Drug Profiles - AGT-181 - ataluren - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - FT-1050 - laronidase chaperone - MultiStem - Oligonucleotide for Mucopolysaccharidosis I - Recombinant Enzyme to Replace Alpha-L-Iduronidase for Hurler Syndrome - Recombinant Enzyme to Target LRP1 for Mucopolysaccharidosis I - RGX-111 - SB-318 - Stem Cell Therapy for Type1 Mucopolysaccharidosis For more information visit http://www.researchandmarkets.com/research/29...saccharido
FATE: 5.67 (+0.17), OPK: 8.90 (+0.26), SGMO: 5.94 (+0.38), PTCT: 34.23 (+2.28), ATHX: 1.14 (-0.01), FOLD: 7.58 (+0.71)
biOasis Announces Listing on OTCQB Exchange
Marketwired - Mon Sep 28, 4:16PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company"
wishes to announce, that as part of its going forward strategy, its current listing on the OTCQX will be changing to a listing on the OTCQB. The Company's trading symbol will remain BIOAF.
BTI.VN: 1.190 (-0.010)
TSX Venture Exchange Daily Bulletins
CNW Group - Thu Aug 27, 3:31PM CDT
TSX VENTURE COMPANIES
Intelligence on: Conjugation Platform Technologies 2015 - Detailed Insights on Future Opportunities
M2 - Thu Aug 20, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nszlzs/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering. The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen. For the industry to continue its rapid development new technologies are essential to increase diversity of approaches, improve the safety and efficacy of the drugs, and target new indications and exploit novel mechanisms of action. 'Intelligence on: Conjugation Platform Technologies' is a scientific report, produced for researchers to review the different technology approaches developed to date and the levels of commercial and scientific validation that has been done on specific platforms. This report focuses on reviewing the available linker and payload technologies suitable for antibody-drug conjugates. Discover what opportunities there are within the global landscape, learn what new conjugation approaches are emerging and read expert perspectives on what the future holds for the field. Providing sought after intelligence on the variety of emerging technologies for antibody drug conjugation, detailed insights will be shared on future opportunities, potential applications as well as current commercial and scientific validation. Key Topics Covered: 1. Introduction, scopes and objectives 2. Antibody conjugates and other payloads 3. Linker technologies 4. Payload platforms 5. Improving payload delivery mechanisms 6. IP challenges, deal structures, mergers and acquisitions; future opportunities 7. Interviews with experts in the field Companies Mentioned - ADC Therapeutics - AREVA Med - Abbvie - Abzena - Actinium Pharmaceuticals - Adimab - Affinicon - Agensys - Algeta - Allozyne - Alpha Cancer Technologies - Ambrx - Amgen - Angiochem - Asana Biosciences - Aspyrian Therapeutics - Astellas - AstraZeneca - BMS - Baxter - Bayer - BiOasis Technologies - BioAlta - Biogen Idec - Biotest - Boehringer Ingelheim - Cancer Research UK - Catalent - Celgene - Celldex - Cellerant Therapeutics - Centrose - Centyrex - Covagen For more information visit http://www.researchandmarkets.com/research/ns...ligence_on
BIIB: 269.16 (-10.72), ATNM: 2.29 (+0.10), AMGN: 149.59 (-0.31), CELGZ: 1.74 (+0.04)
biOasis to extend share purchase warrants exercise date
M2 - Mon Aug 17, 7:35AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE: BTI) said on Friday that it plans to extend the exercise date of its 1,599,477 warrants currently exercisable until 29 August 2015 to 31 December 2015.
BTI.VN: 1.190 (-0.010)
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 - Summarizes all the dormant and discontinued pipeline projects
M2 - Mon Aug 17, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q7drg7/glioblastoma) has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. Summary This, Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AB Science - AbbVie Inc. - Actelion Ltd - Actinium Pharmaceuticals, Inc. - Actinogen Limited - Activartis Biotech GmbH - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advanced Cancer Therapeutics - Advenchen Laboratories, LLC - Agenus, Inc. - AGY Therapeutics, Inc. - Amal Therapeutics SA - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AngioChem Inc. - Apogenix GmbH - Argon Pharma S.L. - Ariad Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Axelar AB - Bexion Pharmaceuticals, LLC. - biOasis Technologies Inc. - BioCancell Ltd - Biomar Microbial Technologies - Bioncotech Therapeutics S.L. - Biovista Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q7...ioblastoma
ATNM: 2.29 (+0.10), ADRO: 22.06 (+0.32), AMBX: (), AZN: 32.23 (-0.16), AMGN: 149.59 (-0.31), AMPE: 3.04 (+0.05), ABBV: 55.64 (-0.40), BMY: 61.44 (+0.93), AAAP: ()
biOasis Announces Extension of Share Purchase Warrants
Marketwired - Fri Aug 14, 12:00PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQX: BIOAF) (the "Company" wishes to announce that it will make an application to extend the exercise date of its 1,599,477 warrants currently exercisable until August 29, 2015 (the "Warrants" . The Warrants were issued with an original term of 12 months in connection with the closing of a private placement financing as announced by the Company on August 29, 2015. A total of 30,530 of the Warrants are held by an insider of the Company who participated in the private placement. The extension of the expiry of the Warrants is exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 ("MI 61-101" by virtue of the exemptions contain in section 5.5(a) and 5.7(1) (a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company issued to an insider does not exceed 25% of its market capitalization.
BTI.VN: 1.190 (-0.010)
biOasis Announces the Successful Delivery to the CNS of an Enzyme Used to Treat Hunter Syndrome
Marketwired - Fri Jul 31, 3:31PM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the completion and assessment of the data in the knockout mouse model of Hunter Syndrome (MPS II) performed in Padova, Italy, by a team led by Dr. Maurizio Scarpa of the Brains for Brain Foundation.
BTI.VN: 1.190 (-0.010)
biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement
Marketwired - Tue Jul 21, 4:01PM CDT
biOasis (OTCQX: BIOAF)(TSX VENTURE: BTI) and Brigham and Women's Hospital Inc. ("BWH" , Harvard Medical School's distinguished teaching hospital, have entered into a collaboration to pursue work in the area of neuro-oncology.
BTI.VN: 1.190 (-0.010)
Brain Metastasis Pipeline Report 2015 - 23 Companies & 30 Drug Profiles
M2 - Fri Jul 10, 2:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nxlq99/brain_metastasis) has announced the addition of the "Brain Metastasis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AngioChem Inc. - BBB Therapeutics B.V. - biOasis Technologies Inc. - Bristol-Myers Squibb Company - Diffusion Pharmaceuticals LLC - e-Therapeutics plc - Exelixis, Inc. - GlaxoSmithKline plc - Hutchison MediPharma Limited - Komipharm International Co., Ltd. - Nanobiotix - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Puma Biotechnology, Inc. - Radius Health, Inc. - Sanofi - Spectrum Pharmaceuticals, Inc. - Tocagen Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - 2B3-101 - ANG-1005 - ANG-4043 - BT-2111 - cabazitaxel - cabozantinib s-malate - dabrafenib mesylate - dacomitinib - Drug for Brain Metastasis - etirinotecan pegol - ETS-2101 - Gene Therapy to Activate p53 for Oncology - HMPL-813 - ipilimumab - KML-001 - lapatinib ditosylate - lucanthone hydrochloride - NBTX-IV - neratinib - nimotuzumab - NMSE-973 - PB-357 - PT-112 - RAD-1901 - radretumab - RRX-001 - transcrocetinate sodium - veliparib - vocimagene amiretrorepvec flucytosine ER For more information visit http://www.researchandmarkets.com/research/nx...metastasis
RDUS: 57.80 (-3.30), PFE: 33.24 (+0.15), SPPI: 6.20 (+0.07), ABBV: 55.64 (-0.40), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), PBYI: 79.41 (+3.89), NKTR: 11.34 (+0.56), NVS: 91.90 (-0.71), EXEL: 5.99 (+0.14)
biOasis Engages Kilmer Lucas for Cross-Border Investor Relations
Marketwired - Mon Jun 08, 4:01PM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced today that it has retained Kilmer Lucas Inc. to provide it with Canadian and U.S. investor relations and strategic advisory services.
BTI.VN: 1.190 (-0.010)
biOasis Enters Into A Collaborative Research and Joint Funding Support Agreement Entitled "Focus on Brain"
Marketwired - Wed May 27, 8:03AM CDT
biOasis (TSX VENTURE: BTI)(OTCQX: BIOAF) today announces that it, in partnership with the National Research Council of Canada and the Universite de Sherbrooke, has been awarded a collaborative research grant by the CQDM and Brain Canada. In their "Focus on Brain" call for proposals, the partners received a number of applications from companies and academic institutions. The focus of the research agreement is to identify a new generation of potential blood-brain barrier (BBB) carrier molecules.
BTI.VN: 1.190 (-0.010)
Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences
CNW Group - Wed May 27, 8:00AM CDT
CQDM, Brain Canada and the Ontario Brain Institute (OBI) award close to $8.5M to six (6) multi-disciplinary and multi-provincial research teams across Canada to address unmet needs in neuroscience within their Focus on Brain strategic initiative. To this amount, $1.5M is added from the various research entities involved as in-kind contributions. This exciting announcement was made today at the annual meeting of the Canadian Association for Neuroscience in the presence of Inez Jabalpurwala, President and CEO of Brain Canada; Mario Chevrette, Vice President, Scientific Affairs of CQDM; and Donald Stuss, President and Scientific Director of OBI.
biOasis Provides Scientific Updates on Its Transcend Programs
Marketwired - Tue May 12, 6:00PM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), has announced results from its Her2+ brain tumor model with its lead therapeutic, MTfp-TZM. The company has also provided a scientific update relating to other programs.
BTI.VN: 1.190 (-0.010)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Pipeline Review, H2 2015 - 10 Companies & 13 Drug Profiles
M2 - Mon Oct 05, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2932sl/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - ArmaGen Technologies, Inc. - Athersys, Inc. - biOasis Technologies Inc. - Fate Therapeutics, Inc. - OPKO Health, Inc. - PTC Therapeutics, Inc. - RegenxBio Inc. - Sangamo BioSciences, Inc. Drug Profiles - AGT-181 - ataluren - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - FT-1050 - laronidase chaperone - MultiStem - Oligonucleotide for Mucopolysaccharidosis I - Recombinant Enzyme to Replace Alpha-L-Iduronidase for Hurler Syndrome - Recombinant Enzyme to Target LRP1 for Mucopolysaccharidosis I - RGX-111 - SB-318 - Stem Cell Therapy for Type1 Mucopolysaccharidosis For more information visit http://www.researchandmarkets.com/research/29...saccharido
FATE: 5.67 (+0.17), OPK: 8.90 (+0.26), SGMO: 5.94 (+0.38), PTCT: 34.23 (+2.28), ATHX: 1.14 (-0.01), FOLD: 7.58 (+0.71)
biOasis Announces Listing on OTCQB Exchange
Marketwired - Mon Sep 28, 4:16PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company"
wishes to announce, that as part of its going forward strategy, its current listing on the OTCQX will be changing to a listing on the OTCQB. The Company's trading symbol will remain BIOAF. BTI.VN: 1.190 (-0.010)
TSX Venture Exchange Daily Bulletins
CNW Group - Thu Aug 27, 3:31PM CDT
TSX VENTURE COMPANIES
Intelligence on: Conjugation Platform Technologies 2015 - Detailed Insights on Future Opportunities
M2 - Thu Aug 20, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nszlzs/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering. The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen. For the industry to continue its rapid development new technologies are essential to increase diversity of approaches, improve the safety and efficacy of the drugs, and target new indications and exploit novel mechanisms of action. 'Intelligence on: Conjugation Platform Technologies' is a scientific report, produced for researchers to review the different technology approaches developed to date and the levels of commercial and scientific validation that has been done on specific platforms. This report focuses on reviewing the available linker and payload technologies suitable for antibody-drug conjugates. Discover what opportunities there are within the global landscape, learn what new conjugation approaches are emerging and read expert perspectives on what the future holds for the field. Providing sought after intelligence on the variety of emerging technologies for antibody drug conjugation, detailed insights will be shared on future opportunities, potential applications as well as current commercial and scientific validation. Key Topics Covered: 1. Introduction, scopes and objectives 2. Antibody conjugates and other payloads 3. Linker technologies 4. Payload platforms 5. Improving payload delivery mechanisms 6. IP challenges, deal structures, mergers and acquisitions; future opportunities 7. Interviews with experts in the field Companies Mentioned - ADC Therapeutics - AREVA Med - Abbvie - Abzena - Actinium Pharmaceuticals - Adimab - Affinicon - Agensys - Algeta - Allozyne - Alpha Cancer Technologies - Ambrx - Amgen - Angiochem - Asana Biosciences - Aspyrian Therapeutics - Astellas - AstraZeneca - BMS - Baxter - Bayer - BiOasis Technologies - BioAlta - Biogen Idec - Biotest - Boehringer Ingelheim - Cancer Research UK - Catalent - Celgene - Celldex - Cellerant Therapeutics - Centrose - Centyrex - Covagen For more information visit http://www.researchandmarkets.com/research/ns...ligence_on
BIIB: 269.16 (-10.72), ATNM: 2.29 (+0.10), AMGN: 149.59 (-0.31), CELGZ: 1.74 (+0.04)
biOasis to extend share purchase warrants exercise date
M2 - Mon Aug 17, 7:35AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE: BTI) said on Friday that it plans to extend the exercise date of its 1,599,477 warrants currently exercisable until 29 August 2015 to 31 December 2015.
BTI.VN: 1.190 (-0.010)
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 - Summarizes all the dormant and discontinued pipeline projects
M2 - Mon Aug 17, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q7drg7/glioblastoma) has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. Summary This, Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AB Science - AbbVie Inc. - Actelion Ltd - Actinium Pharmaceuticals, Inc. - Actinogen Limited - Activartis Biotech GmbH - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advanced Cancer Therapeutics - Advenchen Laboratories, LLC - Agenus, Inc. - AGY Therapeutics, Inc. - Amal Therapeutics SA - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AngioChem Inc. - Apogenix GmbH - Argon Pharma S.L. - Ariad Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Axelar AB - Bexion Pharmaceuticals, LLC. - biOasis Technologies Inc. - BioCancell Ltd - Biomar Microbial Technologies - Bioncotech Therapeutics S.L. - Biovista Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q7...ioblastoma
ATNM: 2.29 (+0.10), ADRO: 22.06 (+0.32), AMBX: (), AZN: 32.23 (-0.16), AMGN: 149.59 (-0.31), AMPE: 3.04 (+0.05), ABBV: 55.64 (-0.40), BMY: 61.44 (+0.93), AAAP: ()
biOasis Announces Extension of Share Purchase Warrants
Marketwired - Fri Aug 14, 12:00PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQX: BIOAF) (the "Company"
wishes to announce that it will make an application to extend the exercise date of its 1,599,477 warrants currently exercisable until August 29, 2015 (the "Warrants" . The Warrants were issued with an original term of 12 months in connection with the closing of a private placement financing as announced by the Company on August 29, 2015. A total of 30,530 of the Warrants are held by an insider of the Company who participated in the private placement. The extension of the expiry of the Warrants is exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 ("MI 61-101" by virtue of the exemptions contain in section 5.5(a) and 5.7(1) (a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company issued to an insider does not exceed 25% of its market capitalization. BTI.VN: 1.190 (-0.010)
biOasis Announces the Successful Delivery to the CNS of an Enzyme Used to Treat Hunter Syndrome
Marketwired - Fri Jul 31, 3:31PM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the completion and assessment of the data in the knockout mouse model of Hunter Syndrome (MPS II) performed in Padova, Italy, by a team led by Dr. Maurizio Scarpa of the Brains for Brain Foundation.
BTI.VN: 1.190 (-0.010)
biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement
Marketwired - Tue Jul 21, 4:01PM CDT
biOasis (OTCQX: BIOAF)(TSX VENTURE: BTI) and Brigham and Women's Hospital Inc. ("BWH"
, Harvard Medical School's distinguished teaching hospital, have entered into a collaboration to pursue work in the area of neuro-oncology. BTI.VN: 1.190 (-0.010)
Brain Metastasis Pipeline Report 2015 - 23 Companies & 30 Drug Profiles
M2 - Fri Jul 10, 2:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nxlq99/brain_metastasis) has announced the addition of the "Brain Metastasis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AngioChem Inc. - BBB Therapeutics B.V. - biOasis Technologies Inc. - Bristol-Myers Squibb Company - Diffusion Pharmaceuticals LLC - e-Therapeutics plc - Exelixis, Inc. - GlaxoSmithKline plc - Hutchison MediPharma Limited - Komipharm International Co., Ltd. - Nanobiotix - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Puma Biotechnology, Inc. - Radius Health, Inc. - Sanofi - Spectrum Pharmaceuticals, Inc. - Tocagen Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - 2B3-101 - ANG-1005 - ANG-4043 - BT-2111 - cabazitaxel - cabozantinib s-malate - dabrafenib mesylate - dacomitinib - Drug for Brain Metastasis - etirinotecan pegol - ETS-2101 - Gene Therapy to Activate p53 for Oncology - HMPL-813 - ipilimumab - KML-001 - lapatinib ditosylate - lucanthone hydrochloride - NBTX-IV - neratinib - nimotuzumab - NMSE-973 - PB-357 - PT-112 - RAD-1901 - radretumab - RRX-001 - transcrocetinate sodium - veliparib - vocimagene amiretrorepvec flucytosine ER For more information visit http://www.researchandmarkets.com/research/nx...metastasis
RDUS: 57.80 (-3.30), PFE: 33.24 (+0.15), SPPI: 6.20 (+0.07), ABBV: 55.64 (-0.40), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), PBYI: 79.41 (+3.89), NKTR: 11.34 (+0.56), NVS: 91.90 (-0.71), EXEL: 5.99 (+0.14)
biOasis Engages Kilmer Lucas for Cross-Border Investor Relations
Marketwired - Mon Jun 08, 4:01PM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced today that it has retained Kilmer Lucas Inc. to provide it with Canadian and U.S. investor relations and strategic advisory services.
BTI.VN: 1.190 (-0.010)
biOasis Enters Into A Collaborative Research and Joint Funding Support Agreement Entitled "Focus on Brain"
Marketwired - Wed May 27, 8:03AM CDT
biOasis (TSX VENTURE: BTI)(OTCQX: BIOAF) today announces that it, in partnership with the National Research Council of Canada and the Universite de Sherbrooke, has been awarded a collaborative research grant by the CQDM and Brain Canada. In their "Focus on Brain" call for proposals, the partners received a number of applications from companies and academic institutions. The focus of the research agreement is to identify a new generation of potential blood-brain barrier (BBB) carrier molecules.
BTI.VN: 1.190 (-0.010)
Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences
CNW Group - Wed May 27, 8:00AM CDT
CQDM, Brain Canada and the Ontario Brain Institute (OBI) award close to $8.5M to six (6) multi-disciplinary and multi-provincial research teams across Canada to address unmet needs in neuroscience within their Focus on Brain strategic initiative. To this amount, $1.5M is added from the various research entities involved as in-kind contributions. This exciting announcement was made today at the annual meeting of the Canadian Association for Neuroscience in the presence of Inez Jabalpurwala, President and CEO of Brain Canada; Mario Chevrette, Vice President, Scientific Affairs of CQDM; and Donald Stuss, President and Scientific Director of OBI.
biOasis Provides Scientific Updates on Its Transcend Programs
Marketwired - Tue May 12, 6:00PM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), has announced results from its Her2+ brain tumor model with its lead therapeutic, MTfp-TZM. The company has also provided a scientific update relating to other programs.
BTI.VN: 1.190 (-0.010)
